SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 10/09/2024 at 07:00, 1 month 14 days ago

Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
Sanofi presents new Beyfortus data at IDWeek 2024, showcasing real-world effectiveness in protecting infants from RSV disease and hospitalization. Beyfortus doses shipped for 2024-2025 RSV season

Sanofi RSV Beyfortus Infants IDWeek
BRIEF

published on 09/27/2024 at 15:40, 1 month 26 days ago

Dupixent Approved in the US as First Biologic for COPD Patients

FDA Approval Clinical Studies COPD Dupixent Biologic Medicine
BRIEF

published on 09/27/2024 at 15:40, 1 month 26 days ago

Dupixent approuvé aux États-Unis comme premier médicament biologique pour les patients atteints de BPCO

MPoC Approbation De La FDA Études Cliniques Dupixent Médecine Biologique
PRESS RELEASE

published on 09/27/2024 at 15:35, 1 month 26 days ago

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
US FDA approves Dupixent as the first-ever biologic medicine for COPD, based on phase 3 studies showing significant reduction in exacerbations and improved lung function. Dupixent is now leading in new-to-brand prescriptions for FDA-approved indications

FDA Approval Dupixent COPD Treatment Biologic Medicine Phase 3 Studies
PRESS RELEASE

published on 09/27/2024 at 15:35, 1 month 26 days ago

Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO
La FDA approuve Dupixent comme premier médicament biologique pour la BPCO aux États-Unis, offrant un nouveau traitement aux patients inadéquatement contrôlés. Résultats positifs des études BOREAS et NOTUS

FDA Traitement Études BPCO Dupixent
BRIEF

published on 09/27/2024 at 13:05, 1 month 26 days ago

Dupixent Authorized in China as First Biologic Medicine for COPD Patients

China Approval COPD Dupixent Biologic Medicine
BRIEF

published on 09/27/2024 at 13:05, 1 month 26 days ago

Dupixent autorisé en Chine comme premier médicament biologique pour les patients atteints de BPCO

Chine MPoC Approbation Dupixent Médecine Biologique
PRESS RELEASE

published on 09/27/2024 at 13:00, 1 month 26 days ago

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Dupixent approved in China as the first-ever biologic medicine for COPD patients, following landmark phase 3 studies. Approval crucial for addressing COPD burden in China

China COPD Dupixent Biologic Medicine Phase 3 Studies
PRESS RELEASE

published on 09/27/2024 at 13:00, 1 month 26 days ago

Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO
Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO, réduit les exacerbations et améliore la fonction respiratoire. Approbation suite à études de phase III

Traitement Chine Approbation BPCO Dupixent
BRIEF

published on 09/21/2024 at 00:41, 2 months 2 days ago

Approbation du Sarclisa aux États-Unis pour le traitement du myélome multiple

FDA Sanofi Myélome Multiple Sarclisa Traitement De Première Ligne

Published on 11/22/2024 at 23:55, 1 day ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 1 day ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 1 day 1 hour ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 1 day 1 hour ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 1 day 1 hour ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 1 day 5 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 1 day 6 hours ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 1 day 6 hours ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 1 day 7 hours ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 1 day 8 hours ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 17:45, 1 day 6 hours ago

IMMERSION : RFA 2023/2024
Published on 11/22/2024 at 16:15, 1 day 7 hours ago

NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Published on 11/22/2024 at 14:35, 1 day 9 hours ago

Communiqué de presse Thales
Published on 11/22/2024 at 14:35, 1 day 9 hours ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 17 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio

View all LES ECHOS COMFI WIRE

News